[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.195.82. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 412
Citations 0
Invited Commentary
December 2018

Treatment of Central Retinal Vein Occlusion—A New Look at a Blast From the Past

Author Affiliations
  • 1Doheny Eye Institute, University of California, Los Angeles
JAMA Ophthalmol. 2018;136(12):1397-1398. doi:10.1001/jamaophthalmol.2018.4997

Prior to the advent of anti–vascular endothelial growth factor (VEGF) therapy, vision loss from macular edema because of central retinal vein occlusion (CRVO) lacked a proven safe and effective treatment. Use of anti-VEGF therapy for vision loss arising from macular edema from CRVO has been reported as early as 2005.1 Since then, multiple randomized clinical trials have described the efficacy and safety of anti-VEGF therapy for the treatment of macular edema and vision loss from CRVO.2,3

×